<DOC>
	<DOCNO>NCT00044343</DOCNO>
	<brief_summary>The purpose study determine efficacy oral investigational drug patient refractory metastatic colorectal cancer receive prior therapy 5-fluorouracil combination irinotecan and/or oxaliplatin .</brief_summary>
	<brief_title>GW572016 , An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Provide sign informed consent . Refractory Stage IV metastatic colorectal cancer . Received least 2 cycle firstline therapy intravenous 5FU ( 5fluorouracil ) combination CPT11 ( irinotecan ) and/or oxaliplatin . No one prior therapy . Tumor tissue available testing . 4 week since firstline cancer regimen . Able swallow retain oral medication . Cardiac ejection fraction within institutional range normal measure MUGA ( Multiple Gated Acquisition Scan ) . Adequate kidney liver function . Adequate bone marrow function . Pregnant lactate female . Conditions would affect absorption oral drug Firstline regimen include 5fluorouracil irinotecan and/or oxaliplatin . Serious medical psychiatric disorder would interfere patient '' safety inform consent . Severe cardiovascular disease cardiac ( heart ) disease require device . Active infection . Brain metastasis . Concurrent cancer therapy investigational therapy . Use oral intravenous steroid . Unresolved unstable , serious toxicity prior therapy . Prior therapy EGFR ( Endothelial Growth Factor Receptor ) and/or erbB2 inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>EGFR inhibitor</keyword>
	<keyword>lapatinib</keyword>
	<keyword>metastatic</keyword>
</DOC>